Erratum: Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial (The Lancet (2014) 383(9916) (533–540) (S0140673613621066) (10.1016/S0140-6736(13)62106-6));Pimavanserin for patients with Parkinson's disease psychosis: A randomised, placebo-controlled phase 3 trial

The Lancet

Volumn 383, Issue 9916, 2014, Pages 533-540

  Cummings, Jeffrey ^a   Isaacson, Stuart ^b   Mills, Roger ^c   Williams, Hilde ^c   Chi Burris, Kathy ^c   Corbett, Anne ^d   Dhall, Rohit ^e   Ballard, Clive ^d  

^a CLEVELAND CLINIC LOU RUVO CENTER FOR BRAIN HEALTH   (United States)

^b Parkinson's Disease and Movement Disorder Center of Boca Raton   (United States)

^c ACADIA PHARMACEUTICALS INC   (United States)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; CLOZAPINE; PIMAVANSERIN; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AGED; ARTICLE; BRAIN DEPTH STIMULATION; CONFUSION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FALLING; FEMALE; FOLLOW UP; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PARKINSON DISEASE; PARKINSON DISEASE PSYCHOSIS; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PLACEBO EFFECT; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SIMPLIFIED ACUTE PHYSIOLOGY SCORE; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VISUAL HALLUCINATION;

EID: 84895904524     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61112-0     Document Type: Erratum

References (31)

1. Parkinson's Disease Foundation. Statistics on Parkinson's. http://www.pdf.org/en/parkinson-statistics (accessed April 16, 2013).
2. Starkstein SE, Brockman S, Hayhow BD. Psychiatric syndromes in Parkinson's disease. Curr Opin Psychiatry 2012; 25: 468-72.
3. Aarsland D, Ballard C, Larsen JP, McKeith I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry 2001; 16: 528-36.
4. Fernandez HH, Okun MS, Rodriguez RL, et al. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study. Int J Neurosci 2009; 119: 2196-205.
5. Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005; 20: 958-63.
6. Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord 2007; 22: 313-18.
7. Shotbolt P, Samuel M, Fox C, David AS. A randomized controlled trial of quetiapine for psychosis in Parkinson's disease. Neuropsychiatr Dis Treat 2009; 5: 327-32.
8. Kurlan R, Cummings J, Raman R, Thal L, and the Alzheimer's Disease Cooperative Study Group. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 2007; 68: 1356-63.
9. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999; 340: 757-63.
10. The French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. Lancet 1999; 353: 2041-42.
11. Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004; 75: 689-95.
12. Vanover KE, Weiner DM, Makhay M, et al. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2- methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther 2006; 317: 910-18.
13. Ballanger B, Strafella AP, van Eimeren T, et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol 2010; 67: 416-21.
14. Creese B, Ballard C, Aarsland D, Londos E, Sharp S, Jones E. Determining the association of the 5HTTLPR polymorphism with delusions and hallucinations in Lewy body dementias. Am J Geriatr Psychiatry 2013; published online April 9. DOI:10.1016/j.jagp.2012.11.001.
15. Dombrovski AY, Mulsant BH, Ferrell RE, et al. Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms. Int Clin Psychopharmacol 2010; 25: 37-45.
16. Harvey L, Reid RE, Ma C, Knight PJ, Pfeifer TA, Grigliatti TA. Human genetic variations in the 5HT2A receptor: a single nucleotide polymorphism identified with altered response to clozapine. Pharmacogenetics 2003; 13: 107-18.
17. Reynolds GP, Templeman LA, Zhang ZJ. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 1021-28.
18. Proitsi P, Lupton MK, Reeves SJ, et al. Association of serotonin and dopamine gene pathways with behavioral subphenotypes in dementia. Neurobiol Aging 2012; 33: 791-803.
19. Meltzer HY, Mills R, Revell S, et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of Parkinson's disease psychosis. Neuropsychopharmacology 2010; 35: 881-92.
20. Friedman JH, Ravina B, Mills R, et al. A multicenter, placebo controlled, double blind trial to examine the safety and efficacy of pimavanserin in the treatment of psychosis in Parkinson's disease. Neurology 2010; 77: abstr 1.
21. Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord 2007; 22: 1061-68.
22. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-84.
23. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-14.
24. Ballard C, Brown R, Fossey J, et al. Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (the CALM-AD trial). Am J Geriatr Psychiatry 2009; 17: 726-33.
25. Andreason N. Scale for the assessment of positive symptoms. Iowa City, IA: University of Iowa, 1984.
26. Voss T, Bahr D, Cummings J, Mills R, Ravina B, Williams H. Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis. Parkinsonism Relat Disord 2013; 19: 295-99.
27. Guy W. ECDEU assessment manual for psychopharmacology-revised (DHEW Publ No ADM 76-338). Rockville, MD: Department of Health, Education, and Welfare Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976: 218-22.
28. Marinus J, Visser M, van Hilten JJ, Lammers GJ, Stiggelbout AM. Assessment of sleep and sleepiness in Parkinson disease. Sleep 2003; 26: 1049-54.
29. Fahn S, Elton RL, and the Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Lieberman A, eds. Recent developments in Parkinson's disease. Florham Park, NJ: Macmillan Health Care Information, 1987: 153-63.
30. Howard R, Phillips P, Johnson T, et al. Determining the minimum clinically important differences for outcomes in the DOMINO trial. Int J Geriatr Psychiatry 2011; 26: 812-17.
31. Ancoli-Israel S, Vanover KE, Weiner DM, Davis RE, van Kammen DP. Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers. Sleep Med 2011; 12: 134-41.